[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Pino Rivero V, González Palomino A, Pantoja Hernández CG, Marcos García M, Trinidad Ruiz G, Pardo Romero G, Blasco Huelva A: [Sinonasal cystic adenoid carcinoma with epiphora and orbital involvement. Report of a case and review of the literature]. An Otorrinolaringol Ibero Am; 2005;32(3):245-52
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sinonasal cystic adenoid carcinoma with epiphora and orbital involvement. Report of a case and review of the literature].
  • [Transliterated title] Carcinoma adenoide quístico nasosinusal con epífora y afectación orbitaria. Presentación de un caso y revisión de la literatura.
  • The ENT exam showed a bleeding red mass in left nasal fossa and CT joint to IRM revealed a tumoral process on that level and informed about its extension to adyacents structures (cavum, ethmoides, sphenoids and maxillary sinus).
  • The biopsy was positive for cystic adenoid carcinoma.
  • One year later we found recurrence on the left orbital floor and maxilar sinus.
  • The Oncology Department informed that it was not possible a treatment with radiotherapy or chemotherapy because the low sensitivity of that lesion those treatment.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Lacrimal Apparatus Diseases / pathology. Orbital Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001694.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 14
  •  go-up   go-down


2. Day TA, Beas RA, Schlosser RJ, Woodworth BA, Barredo J, Sharma AK, Gillespie MB: Management of paranasal sinus malignancy. Curr Treat Options Oncol; 2005 Jan;6(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of paranasal sinus malignancy.
  • Malignancies of the nasal cavity and paranasal sinuses represent a wide spectrum of histologies, tissues of origin, and anatomic primary sites.
  • The inherent difficulty in generalizing treatment approaches is obvious, given the numerous variables associated with the broadly-based term, paranasal sinus malignancy (PNSCa).
  • Nevertheless, the majority of epithelial and salivary malignancies of this region (ie, squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, sinonasal undifferentiated carcinoma, and esthesioneuroblastoma) require surgical intervention as part of any treatment regimen.
  • Nonepithelial malignancies, including the wide variety of sarcomas arising in this region, most commonly require multimodality treatment including chemotherapy, radiation, and/or surgery for definitive treatment.
  • Moreover, the proximity of the nasal cavity and paranasal sinuses to structures including the orbit, dura, brain, cranial nerves, and carotid arteries mandates careful radiologic and neurologic evaluations throughout the course of the disease.
  • However, additional clinical trials are necessary to systematically evaluate the locoregional control, organ-preservation strategies, and survival related to the variety of treatments currently available.
  • [MeSH-major] Carcinoma / surgery. Melanoma / surgery. Paranasal Sinus Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diet. Humans. Life Style. Prognosis. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):486-91 [12243826.001]
  • [Cites] Head Neck. 1995 Jul-Aug;17(4):303-11 [7672971.001]
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Med Pediatr Oncol. 1999 Oct;33(4):362-71 [10491544.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):335-41 [14716769.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):219-23 [10439167.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):948-55 [15313865.001]
  • [Cites] Head Neck Surg. 1980 May-Jun;2(5):410-9 [7364592.001]
  • [Cites] Am J Otolaryngol. 2004 May-Jun;25(3):162-6 [15124164.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1157-62 [11583200.001]
  • [Cites] Oral Oncol. 2002 Jul;38(5):450-9 [12110339.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):130-6 [11463451.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1871-6 [12368633.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):163-94 [11195409.001]
  • [Cites] Otolaryngol Clin North Am. 1995 Dec;28(6):1239-57 [8927395.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Jul;129(1):77-84 [12869921.001]
  • [Cites] Otolaryngol Clin North Am. 2004 Apr;37(2):473-87 [15064075.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8 [12117328.001]
  • [Cites] Nature. 1987 Oct 15-21;329(6140):645-7 [3657988.001]
  • [Cites] Am J Rhinol. 2002 Jul-Aug;16(4):221-7 [12222948.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):158-68 [12694834.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Mar;3(2):84-9 [2031888.001]
  • [Cites] Am J Rhinol. 2002 Sep-Oct;16(5):281-6 [12422974.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(2-3):84-9 [15305080.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Oncology (Williston Park). 1992 Jan;6(1):43-50; discussion 55-6 [1531603.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):361-9 [9607352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):283-9 [9308929.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):510-4, 516-7 [12199167.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):594-611 [12717245.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):635-40 [10764010.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):290-4 [11452937.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 1;136(1):53-7 [12165452.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1405-10 [11870186.001]
  • [Cites] Strahlenther Onkol. 2003 Apr;179(4):233-40 [12707712.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):197-201 [11936913.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):204-13 [10623711.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):743-6 [8318204.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):147-54 [14697432.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):9-15 [15100926.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1996;50(1):19-24 [8669267.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10 (3):192-202 [3953940.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5108-12 [8221646.001]
  • [Cites] Head Neck. 2004 May;26(5):435-41 [15122660.001]
  • [Cites] Head Neck. 2003 Oct;25(10):791-8 [12966502.001]
  • [Cites] Head Neck Surg. 1980 Jul-Aug;2(6):497-508 [6248488.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2000;54(2):221-32 [10892511.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Jan;3(1):17-21 [1705815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):823-9 [9369129.001]
  • [Cites] Epidemiology. 1998 Sep;9(5):518-24 [9730030.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):816-21 [24770459.001]
  • [Cites] J Laryngol Otol. 1992 Dec;106(12):1063-6 [1487661.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1002-10 [7760173.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1079-83 [12220216.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 1):1450-5 [12172261.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):208-10 [10439164.001]
  • [Cites] Head Neck. 1994 Nov-Dec;16(6):574-7 [7822181.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1101-7 [14652810.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Mar;129(3):334-7 [12622544.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1700-11 [10547542.001]
  • [Cites] Head Neck. 2004 Apr;26(4):322-30 [15054735.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):657-61 [1730116.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):255-64 [10421261.001]
  • [Cites] J Laryngol Otol. 1998 Jul;112(7):628-33 [9775291.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3743-9 [11268448.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Head Neck. 2004 Jul;26(7):584-93 [15229900.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):167-86 [15062368.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):147-57 [11936821.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Mar;120(3):387-90 [10064643.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):776-84 [12573765.001]
  • [Cites] Radiother Oncol. 1991 Jul;21(3):193-200 [1924855.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):932-7 [15333652.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):105-12 [12704690.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1241-57, xi [11728944.001]
  • [Cites] Am J Epidemiol. 1994 Aug 15;140(4):340-9 [8059769.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1597-604 [12459626.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):101-7 [10361593.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):1-8 [15100925.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Oct;46(5):310-5 [14628249.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):318-31 [11567805.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15610711.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


3. Jansen EP, Keus RB, Hilgers FJ, Haas RL, Tan IB, Bartelink H: Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys; 2000 Aug 1;48(1):27-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?
  • PURPOSE: To determine the contribution of debulking surgery on local control and survival in paranasal sinus tumors.
  • METHODS AND MATERIALS: Between 1977 and 1996, 73 patients (50 male: 23 female) with a paranasal sinus carcinoma were treated.
  • The histology distribution was as follows: squamous cell carcinoma, 55%; adenocarcinoma, 19%; adenoid cystic carcinoma, 11%; and undifferentiated carcinoma, 15%.
  • Treatment consisted of surgery only in 3, chemotherapy only in 1, radiotherapy only in 18, both surgery and radiotherapy in 50 patients.
  • One patient did not receive any treatment at all.
  • Three patients had concurrent chemotherapy.
  • However, combination treatment gave significantly better 5-year overall survival (OS) (60% vs. 9%; p = 0.001) and 5-year disease-free survival (DFS) (53% vs. 6%; p < 0. 0001).
  • Cox-regression analysis showed that pathologic N status (p = 0.04), palliative intention of treatment (p = 0.018), clinical orbital invasion (p = 0.003), and orbital wall invasion (p = 0.003) were parameters significantly associated with poor local control.
  • Total radiation dose of greater than 65 Gy (p = 0.05) and treatment consisting of radiotherapy alone (p = 0.002) were associated with worse overall survival; for disease-free survival clinical orbital invasion (p = 0.0005), age of greater than 65 years (p = 0.013) and pathologic T4 classification (p = 0.002) were significant factors for an unfavorable outcome.
  • In 19 of 73 patients, 26 serious (mainly ophthalmological) complications were reported; in the majority of these, the visual tract was (partly) included in the treatment fields because of tumor extension.
  • To analyze on which basis patients were selected for the combination therapy, a logistic regression was performed, concluding that clinical T4 classification (p = 0.05), radiological evidence of skull base invasion (p = 0.005), age of greater than 65 years (p = 0.026), radiological evidence of nasopharynx invasion (p = 0.02), clinical suspicion of palate invasion (p = 0.02), and radiological evidence of skin invasion (p = 0.009) were associated with choosing radiotherapy alone.
  • CONCLUSION: Debulking surgery of paranasal sinus malignancies followed by high-dose radiotherapy to the involved sites was associated with better survival and (although not statistically significant) local control.
  • We favor this combination regimen because the surgery gives quick relief of complaints and, at the same time, offers an excellent histologically proven staging method, enabling radiotherapy to be adjusted to the involved sites, thereby decreasing the risk of complications.
  • [MeSH-major] Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cause of Death. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Radiation Injuries / therapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10924968.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


Advertisement
4. Wiseman SM, Popat SR, Rigual NR, Hicks WL Jr, Orner JB, Wein RO, McGary CT, Loree TR: Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases. Ear Nose Throat J; 2002 Aug;81(8):510-4, 516-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases.
  • We retrospectively reviewed 35 cases of adenoid cystic carcinoma that had originated in the minor salivary glands of the paranasal sinuses or nasal cavity.
  • Twenty patients had been treated with surgery and adjuvant radiotherapy, 10 patients with surgery alone, three with radiotherapy alone, and two with concurrent radiotherapy and chemotherapy.
  • During the study, 22 patients developed recurrent disease--11 locally; three distantly; seven locally and distantly; and one locally, regionally, and distantly.
  • Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity is an aggressive neoplasm that results in a high incidence of both local recurrence and distant metastasis, regardless of treatment modality.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / epidemiology. Nose Neoplasms / diagnosis. Nose Neoplasms / epidemiology. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12199167.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


5. Takagi D, Fukuda S, Furuta Y, Yagi K, Homma A, Nagahashi T, Inuyama Y: Clinical study of adenoid cystic carcinoma of the head and neck. Auris Nasus Larynx; 2001 May;28 Suppl:S99-102
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of adenoid cystic carcinoma of the head and neck.
  • OBJECTIVE: We examined prognostic factors and outcome of the primary treatment in patients with adenoid cystic carcinoma (ACC) of the head and neck.
  • Patients with major salivary gland ACC obtained the best 10-year survival rate (83%), while those with paranasal sinus ACC had the worst survival rate (33%).
  • Chemotherapy failed in some patients and was not dramatically effective by itself.
  • Long-term follow-up is necessary for better prognosis of patients treated with radical treatment regimens.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Head and Neck Neoplasms / surgery

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11683353.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Tse DT, Benedetto P, Morcos JJ, Johnson TE, Weed D, Dubovy S: An atypical presentation of adenoid cystic carcinoma of the lacrimal gland. Am J Ophthalmol; 2006 Jan;141(1):187-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical presentation of adenoid cystic carcinoma of the lacrimal gland.
  • PURPOSE: To report a case of lacrimal gland adenoid cystic carcinoma (ACC) with an atypical initial presentation and to postulate an anatomical explanation for this unusual biologic behavior.
  • METHODS: An orbital magnetic resonance imaging study of a 58-year-old man who complained of progressive diplopia and orbital discomfort disclosed a soft tissue mass in the left cavernous sinus and orbital apex.
  • He underwent two cycles of intraarterial cytoreductive chemotherapy followed by a left medial maxillectomy with sphenoethmoidectomy, orbital exenteration, and chemoradiation.
  • CONCLUSIONS: In patients presenting with an infiltrative mass in the cavernous sinus or orbital apex, metastatic disease from an occult lacrimal gland primary should be considered, even with a normal-appearing lacrimal gland.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Orbital Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386996.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / P30 EY 014801
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Samant S, Robbins KT, Vang M, Wan J, Robertson J: Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg; 2004 Aug;130(8):948-55
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer.
  • OBJECTIVE: To report the long-term efficacy of a combined regimen of intra-arterial high-dose cisplatin chemotherapy and concomitant radiation therapy followed by organ-sparing surgery when possible in the treatment of advanced paranasal sinus cancer.
  • Patients Nineteen patients with advanced paranasal sinus malignancies with a minimum follow-up of 2 years.
  • Malignancies included 14 squamous cell carcinomas (74%), 2 adenocarcinomas (10%), 2 adenoid cystic carcinomas (10%), and 1 undifferentiated carcinoma (5%).
  • Intervention Treatment consisted of preoperative radiation therapy (2.0 Gy/fraction per day; total dose, 50 Gy in 5 weeks) given concomitantly with 3 to 4 weekly infusions of intra-arterial cisplatin (150 mg/m(2) per week) and systemic sodium thiosulfate neutralization.
  • The regimen included planned surgery performed approximately 8 weeks after completion of radiation therapy.
  • One patient died of myocardial infarction during treatment.
  • No other treatment-limiting toxic effect was noted.
  • Except for cataract in 2 patients, no visual loss developed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Ethmoid Sinus / pathology. Ethmoid Sinus / surgery. Maxillary Sinus / pathology. Maxillary Sinus / surgery. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Computer-Assisted. Surgical Procedures, Operative
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / mortality. Prospective Studies. Radiation Dosage. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313865.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Mozet C, Stumpp P, Mekonnen B, Dietz A: [Therapeutic options in sinunasal adenoid cystic carcinomas--a case report and review]. Laryngorhinootologie; 2009 Oct;88(10):631-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options in sinunasal adenoid cystic carcinomas--a case report and review].
  • [Transliterated title] Behandlungsstrategie bei sinunasalen adenoidzystischen Karzinomen--Ein Fall mit Literaturübersicht.
  • BACKGROUND: Adenoid cystic carcinomas (ACC) in sinunasal compartments are often not completely resectable.
  • We discuss both, surgical margins and functional results preoperatively and postoperative options for adjuvant therapy.
  • The former opinion of a resistance of ACC towards chemotherapy or irradiation seems to be outdated, even though consensus about therapeutic strategies is still missing.
  • MATERIAL AND METHODS: We discuss therapeutic options and compare data from literature regarding the best adjuvant therapy with the case of a 25-year-old patient with an advanced ACC of the left fossa pterygopalatina.
  • Further we discuss alternative therapeutic options like neutron irradiation, chemotherapy or targeted therapy.
  • RESULTS: With the described therapeutic strategy we reached an optimal local tumor control with unlimited visus and without functional and cosmetic restrictions up to now.
  • CONCLUSION: Organ preserving surgery and adjuvant radiochemotherapy even in combination with taxol and carboplatin seems to be a sufficient therapeutic option in treating advanced sinunasal ACC, and might not have any prognostic disadvantages to radical surgery.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Neoplasm, Residual / surgery. Paranasal Sinus Neoplasms / surgery. Pterygopalatine Fossa / surgery. Skull Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Endoscopy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Staging. Orbit / pathology. Orbit / surgery. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Sphenoid Bone / pathology. Sphenoid Bone / surgery. Surgery, Computer-Assisted. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19813159.001).
  • [ISSN] 1438-8685
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 51
  •  go-up   go-down


9. Hallacq P, Labrousse F, Roullet B, Orsel S, Bessede JP, Moreau JJ: [Adenoid cystic carcinomas invading the skull base. Apropos of 4 cases and review of the literature]. Neurochirurgie; 2001 Dec;47(6):542-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinomas invading the skull base. Apropos of 4 cases and review of the literature].
  • Head and neck adenoid cystic carcinomas may invade the adjacent skull base by bone lysis and/or by perinervous and perivascular spread within the skull base foramina.
  • Neurosurgical decision making is not well defined regarding the extent of intracranial tumor component removal, as neurosurgical expertise is limited for this peculiar type of tumors.
  • Over a 13-year period, four adenoid cystic carcinomas invading the skull base were operated on at our institution: two tumors originated in the parotid gland, one in the sphenoid sinus, and one in the ethmoid sinus.
  • One patient with advanced metastatic disease was submitted to chemotherapy.
  • Surgery remains the gold standard treatment for adenoid cystic carcinomas invading the skull base.
  • However, in our opinion a large tumor removal, without or with bone osteotomies, but without sacrifice of cranial nerves, cavernous sinus, internal carotid artery, and of the orbit allows patient survival with an acceptable comfort and absence of psychological distress due to disfigurating surgery nor surgically induced neurological functional deficit.
  • The place of chemotherapy has, yet, to be determined.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Ethmoid Sinus / surgery. Paranasal Sinus Neoplasms / surgery. Parotid Neoplasms / surgery. Skull Base Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915613.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Cantù G, Bimbi G, Fabiani F, Guzzo M, Mattavelli F, Pizzi N, Riccio S, Squadrelli M: [Lymph node metastases in paranasal sinus carcinoma: prognostic value and treatment]. Acta Otorhinolaryngol Ital; 2002 Oct;22(5):273-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymph node metastases in paranasal sinus carcinoma: prognostic value and treatment].
  • The purpose of this report is to assess, on the basis of a sizeable study, the prognostic value of lymph node metastases in paranasal sinus carcinoma and, in particular, in squamous cell carcinoma of the maxillary sinus.
  • We have reviewed the charts of 601 cases of paranasal sinus carcinoma between 1970 and 1999.
  • All of the patients were treated surgically, alone or associated with chemotherapy and/or radiotherapy.
  • The maxillary sinus tumors numbered 379 (153 squamous cell carcinomas, 15 undifferentiated carcinomas, 94 adenoid cystic carcinomas, 19 adenocarcinomas, 98 mesenchymal tumors and rare forms) and the ethmoidal tumors were 222 (117 adenocarcinomas, 27 squamous cell carcinomas, 16 adenoid cystic carcinomas, 13 undifferentiated carcinomas, 49 other histological forms).
  • Lymph node metastases in ethmoidal tumors were rare, with the exception of undifferentiated carcinoma (46.1%).
  • The percentages of metastatic squamous cell carcinoma of the maxillary sinus upon presentation were: T2 15.5%, T3 7%, and T4 4%.
  • The metastases successive to treatment of the primary tumor were: T2 16.9%, T3 8.8%, and T4 12%.
  • 75% of these late metastases occurred contemporaneously with a recurrence of T and only 5 (25%) constituted the single reawakening of disease; four of these patients underwent neck surgery and were cured operatively.
  • The NED survival rate at least two years after T therapy in patients free from metastases was 50.4%, against 25% in those with initial or distant metastases (T2 72.9% vs. 30.4%, T3 37.5% vs. 22.2%, and T4 28.6% vs. 0%).
  • In conclusion, squamous cell carcinomas of the maxillary sinus which have extended to the oral cavity (T2) show greater lymph node propagation than those of the superoposterior portion (T3-T4).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Maxillary Sinus / radiation effects. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12510338.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Diba R, Saadati HG, Esmaeli B: Outcomes of dacrocystorhinostomy in patients with head and neck tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):5584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor diagnoses were as follows: squamous cell carcinoma (SCCA), 18 patients (16 had paranasal-sinus SCCA and 2 had skin SCCA); chondrosarcoma, 3; sinonasal carcinoma, 2; adenoid cystic carcinoma, 2; sinonasal papilloma, 2; esthesioneuroblastoma, 1; hemangiopericytoma,1; ameloblastoma,1; and ostoesarcoma,1.
  • Twenty-one patients had a maxillectomy and 7 patients had other sinus surgeries before DCR.
  • Six patients had had silicone intubation at the time of maxillectomy but later developed epiphora and nasolacrimal duct blockage.
  • Ten patients had radiotherapy and 14 had chemotherapy and radiotherapy before DCR.
  • The mean time between completion of radiotherapy and DCR was 24 months (median, 31.5 months), and the mean time between completion of chemotherapy and DCR was 21.5 months (median, 12.5 months).
  • None of the patients who had had radiotherapy developed osteoradionecrosis.
  • Two patients had mild wound infections, which resolved after 1 week of systemic antibiotic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Diaz EM Jr, Kies MS: Chemotherapy for skull base cancers. Otolaryngol Clin North Am; 2001 Dec;34(6):1079-85, viii

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for skull base cancers.
  • This article focuses on treatment options for select skull base problems that have decreased post-treatment morbidity and, in many cases, improved survival.
  • The select skull base cancers covered include nasopharyngeal carcinoma, squamous cell carcinoma of the paranasal sinuses, sinonasal undifferentiated carcinoma, neuroendocrine carcinoma, esthesioneuroblastoma, and salivary gland carcinoma.
  • [MeSH-major] Skull Base Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Squamous Cell / drug therapy. Esthesioneuroblastoma, Olfactory / drug therapy. Humans. Paranasal Sinus Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11728933.001).
  • [ISSN] 0030-6665
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


13. DeMonte F, Ginsberg LE, Clayman GL: Primary malignant tumors of the sphenoidal sinus. Neurosurgery; 2000 May;46(5):1084-91; discussion 1091-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant tumors of the sphenoidal sinus.
  • OBJECTIVE: Neoplasms of the paranasal sinuses account for 0.2 to 0.8% of all cancers and for 2 to 3% of head and neck cancers.
  • Primary involvement of the sphenoidal sinus has been reported to occur in only 1 to 2% of all paranasal sinus tumors.
  • Tumors at this site commonly present with cranial neuropathies and require multidisciplinary treatment.
  • METHODS: During a 21-year period, 27 patients with primary sphenoidal sinus tumors were evaluated.
  • The records of all remaining patients were reviewed for the following parameters: age, sex, and ethnic origin; presenting symptoms and signs; radiological features and sites of tumor extension; pathological findings; prior treatments; surgical approaches and extent of resection; adjuvant therapy; complications; and patient outcome.
  • The most common diseases were squamous cell carcinoma (n = 9), adenoid cystic carcinoma (n = 4), chondrosarcoma (n = 3), and neuroendocrine carcinoma (n = 3).
  • Treatments included surgery (n = 1), surgery and radiotherapy (n = 6), surgery and chemotherapy (n = 3), surgery, radiotherapy, and chemotherapy (n = 4), chemotherapy (n = 5), chemotherapy and radiotherapy (n = 3), and radiotherapy (n = 2).
  • The 2-year survival rate for patients with squamous cell carcinoma was 44%.
  • CONCLUSION: Headache and visual disturbances are common symptoms of sphenoidal sinus tumors.
  • It is advantageous if the surgical team has had experience with both open and endoscopic approaches to the sphenoidal sinus.
  • Patient outcome is maximized by the use of aggressive multidisciplinary therapy.
  • [MeSH-major] Paranasal Sinus Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Chondrosarcoma / diagnosis. Chondrosarcoma / mortality. Chondrosarcoma / pathology. Chondrosarcoma / surgery. Combined Modality Therapy. Endoscopy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10807240.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


14. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors of the nasal cavity and paranasal sinuses.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • There were 25 squamous cell carcinomas, 14 undifferentiated carcinomas, 31 minor salivary gland tumors (adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma), 8 esthesioneuroblastomas, and 1 transitional cell carcinoma.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Vedrine PO, Thariat J, Merrot O, Percodani J, Dufour X, Choussy O, Toussaint B, Dassonville O, Klossek JM, Santini J, Jankowski R: Primary cancer of the sphenoid sinus--a GETTEC study. Head Neck; 2009 Mar;31(3):388-97
Genetic Alliance. consumer health - Sinus cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cancer of the sphenoid sinus--a GETTEC study.
  • BACKGROUND: Primary involvement of the sphenoid sinus occurs in 2% of all paranasal sinus tumors and is associated with dismal prognosis.
  • METHODS: A total of 23 patients were treated for a primary cancer of the sphenoid sinus from 1988 to 2004.
  • Charts were reviewed for patient-, tumor-, and treatment-related parameters.
  • Pathologic findings included adenoid cystic carcinoma, adenocarcinoma, lymphoma, squamous cell carcinoma, sarcoma, neuroendocrine carcinoma, melanoma, and malignant hemangiopericytoma.
  • Radiotherapy was performed in 18 patients and chemotherapy in 12.
  • Surgery was rarely complete because of advanced stages at presentation, but it yielded better outcomes than other treatments without surgery in non lymphoma-cases.
  • Surgery, including debulking surgery, may be preferred to combined modality treatments without surgery.
  • Highly conformal radiotherapy (adjuvant or definitive) should be encouraged and optimized with concurrent chemotherapy in advanced stages.
  • Aggressive multidisciplinary management including surgery, chemotherapy, and radiotherapy should be encouraged and adapted on histology and tumor extensions.
  • [MeSH-major] Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / therapy. Chemotherapy, Adjuvant. Cranial Nerve Diseases / complications. Diagnostic Imaging. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / therapy. Meningioma / mortality. Meningioma / pathology. Meningioma / therapy. Middle Aged. Multivariate Analysis. Plasmacytoma / mortality. Plasmacytoma / pathology. Plasmacytoma / therapy. Preoperative Care. Radiotherapy, Adjuvant. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972425.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


16. Issing PR, Hemmanouil I, Wilkens L, Karstens H, Lenarz T: [Long term results in adenoidcystic carcinoma]. Laryngorhinootologie; 2002 Feb;81(2):98-105
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long term results in adenoidcystic carcinoma].
  • BACKGROUND: Due to the discreet initial symptoms and the locally aggressive infiltration with perineural spread the adenoidcystic carcinoma (ACC) presents a special diagnostical and therapeutical challenge.
  • The exact distribution of the ACC was: parotid gland (n = 18), submandibular gland (n = 8), oral cavity (n = 10), paranasal sinuses (n = 11), nasopharynx (n = 4) and larynx (n = 3).
  • The most common symptoms were a tumor-related swelling and pain which persisted for a duration of several months after final diagnosis could be established.
  • No definitive differentiation was possible in 10 specimens.
  • Except one patient all 54 underwent surgical therapy.
  • Postoperative radiotherapy was additionally given in 25 cases which was combined with a chemotherapy in 6 patients.
  • Lymphnode metastases were observed in 13 patients after a latency of 3.3 years in average, but predominantly pulmonary metastases as distant spread developed in 18 patients after 5.8 years significantly later.
  • CONCLUSIONS: Due to the uncommon biological behaviour with a slow growth on the one hand side and an aggressive local invasion on the other hand side the ACC can be regarded as a challenging malignant disease for the clinician whose adequate therapy does not allow any standardized regime.
  • [MeSH-major] Carcinoma, Adenoid Cystic. Mouth Neoplasms. Otorhinolaryngologic Neoplasms. Paranasal Sinus Neoplasms. Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / surgery. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / surgery. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local. Parotid Neoplasms / diagnosis. Parotid Neoplasms / surgery. Parotid Neoplasms / therapy. Prognosis. Retrospective Studies. Submandibular Gland. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11914946.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Chen AM, Daly ME, Bucci MK, Xia P, Akazawa C, Quivey JM, Weinberg V, Garcia J, Lee NY, Kaplan MJ, El-Sayed I, Eisele DW, Fu KK, Phillips TL: Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):141-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?
  • PURPOSE: To compare clinical outcomes of patients with carcinomas of the paranasal sinuses and nasal cavity according to decade of radiation treatment.
  • METHODS AND MATERIALS: Between 1960 and 2005, 127 patients with sinonasal carcinoma underwent radiotherapy with planning and delivery techniques available at the time of treatment.
  • Nineteen patients (15%) received chemotherapy.
  • The most common histology was squamous cell carcinoma (83 patients).
  • There were no significant differences in any of these endpoints with respect to decade of treatment or radiotherapy technique (p > 0.05, for all).
  • CONCLUSION: Although we did not detect improvements in disease control or overall survival for patients treated over time, the incidence of complications has significantly declined, thereby resulting in an improved therapeutic ratio for patients with carcinomas of the paranasal sinuses and nasal cavity.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiation Injuries / prevention & control. Radiotherapy / adverse effects. Radiotherapy / trends. Radiotherapy, Conformal / adverse effects. Radiotherapy, Intensity-Modulated / adverse effects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459609.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Madison Michael L 2nd, Sorenson JM, Samant S, Robertson JH: The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation. J Neurooncol; 2005 Mar;72(1):67-75
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation.
  • INTRODUCTION: Malignancies of the nasal and paranasal sinuses are uncommon tumors, accounting for only 3% of all aerodigestive tract neoplasms.
  • Despite advances in surgical techniques and continued evolution of adjuvant therapies, the 5-year mortality remains unusually high at greater than 50%.
  • In 1996, we begin utilizing a novel strategy in the treatment of advanced sinonasal carcinomas.
  • This consisted of neoadjuvant selective intra-arterial cisplatin with concurrent radiation therapy (acronym RADPLAT) followed by a conservative craniofacial resection.
  • METHODS: Between July 1996 and April 2003, 11 patients with advanced sinonasal malignancies underwent treatment utilizing the RADPLAT protocol followed by a planned surgical resection via a craniofacial approach.
  • RESULTS: Histopathological analysis of the tumors revealed seven squamous cell carcinomas (64%), two adenocarcinomas (18%), one adenoid cystic carcinoma (9%), and one sinonasal undifferentiated carcinoma (9%).
  • CONCLUSIONS: The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation results in a significant improvement in survival.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Carcinoma / radiotherapy. Cisplatin / administration & dosage. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoadjuvant Therapy / methods. Premedication. Radiation-Sensitizing Agents / administration & dosage. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):263-71 [9226312.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 20;85(2):95-111 [8418313.001]
  • [Cites] Head Neck. 1998 Mar;20(2):97-105 [9484939.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):352-8 [3661836.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Apr;118(4):367-72 [1313248.001]
  • [Cites] Acta radiol. 1954 Aug;42(2):149-72 [13197115.001]
  • [Cites] Otolaryngol Clin North Am. 1995 Dec;28(6):1239-57 [8927395.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14 (1):11-22 [3335447.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jun;127(6):687-90 [11405869.001]
  • [Cites] Head Neck. 2000 Oct;22(7):687-93 [11002324.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):429-35 [3721885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):765-73 [7960977.001]
  • [Cites] Am J Surg. 1988 Sep;156(3 Pt 1):187-90 [3421426.001]
  • [Cites] J Neurosurg. 1968 Apr;28(4):341-50 [5643926.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):361-9 [9607352.001]
  • [Cites] Am J Surg. 1985 Oct;150(4):406-13 [4051102.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):190-6 [3965080.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):457-65 [9690538.001]
  • [Cites] AMA Arch Otolaryngol. 1953 Dec;58(6):704-9 [13103898.001]
  • [Cites] Cancer. 1963 Oct;16:1293-301 [14074213.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Nov;120(11):1203-8 [7917203.001]
  • [Cites] Head Neck. 2000 Dec;22(8):772-80 [11084637.001]
  • [Cites] Acta Oncol. 1997;36(1):27-31 [9090960.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):307-12 [8056574.001]
  • [Cites] Radiol Med. 1994 Sep;88(3):291-4 [7938737.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):141-6 [11177030.001]
  • [Cites] Curr Oncol Rep. 2001 Jan;3(1):59-65 [11123871.001]
  • [Cites] J Clin Oncol. 1986 Jul;4(7):1121-6 [3522819.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):419-22 [7977964.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):21-7 [9886693.001]
  • [Cites] J Otolaryngol. 1978 Oct;7(5):379-88 [105151.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):743-6 [8318204.001]
  • [Cites] Laryngoscope. 1989 Nov;99(11):1130-6 [2811551.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 12):28-34 [7992064.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2261-6 [3697928.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):10-5 [2738628.001]
  • [Cites] Oncology (Williston Park). 1997 Dec;11(12):1781-90, 1796; discussion 1796, 179 [9436185.001]
  • [Cites] Cancer. 1954 Sep;7(5):991-4 [13199776.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1989 Apr;115(4):503-11 [2466470.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Laryngoscope. 1994 May;104(5 Pt 1):553-5 [8189985.001]
  • [Cites] Head Neck Surg. 1988 Mar-Apr;10(4):219-24 [3235351.001]
  • [Cites] Head Neck. 1999 May;21(3):185-91 [10208659.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1296-304; discussion 1304-5 [11126900.001]
  • [Cites] Am J Surg. 1973 Oct;126(4):469-76 [4743833.001]
  • [Cites] Head Neck. 1994 Nov-Dec;16(6):574-7 [7822181.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Aug;13(4):769-75, vii [10494512.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):471-9; discussion 479-80 [8837798.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Dec;127(12):1451-6 [11735813.001]
  • [Cites] J Otolaryngol. 1984 Jun;13(3):141-6 [6100551.001]
  • [Cites] Laryngoscope. 1994 Aug;104(8 Pt 1):940-5 [8052078.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3333-9 [11454880.001]
  • [Cites] J Craniofac Surg. 1997 Sep;8(5):405-12 [9482083.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):167-73 [11054520.001]
  • [Cites] Semin Oncol. 1991 Feb;18(1 Suppl 3):34-48 [2003226.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] Ann Intern Med. 1982 Dec;97(6):845-51 [6890785.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Apr;25(4):619-25 [2714338.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1476-82 [11920504.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):541-9 [10701732.001]
  • [Cites] Am Surg. 1990 May;56(5):327-30 [2334076.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Cancer. 1985 Jul 1;56(1):57-62 [4005793.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):328-32 [2802037.001]
  • [Cites] J Am Med Assoc. 1948 Aug 7;137(15):1306; passim [18870026.001]
  • [Cites] Cancer Commun. 1990;2(2):93-100 [2372473.001]
  • [Cites] Am J Surg. 1963 Nov;106:698-703 [14078719.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63 [7960976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):113-6 [8416866.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):508-13 [6885504.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1925-32 [11064349.001]
  • [Cites] Am J Surg. 1966 Oct;112(4):591-6 [5915306.001]
  • (PMID = 15803378.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • However, the T-stage distribution was significantly different between the EEA group and the CEA group.
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Other, less common tumors included adenoid cystic carcinoma (7%), neuroendocrine carcinoma (4%), and sinonasal undifferentiated carcinoma (2%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-major] Endoscopy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Diba R, Saadati H, Esmaeli B: Outcomes of dacryocystorhinostomy in patients with head and neck tumors. Head Neck; 2005 Jan;27(1):72-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The tumor diagnoses were squamous cell carcinoma (n = 18), chondrosarcoma (n = 3), sinonasal carcinoma (n = 2), adenoid cystic carcinoma (n = 2), sinonasal papilloma (n = 2), esthesioneuroblastoma (n = 1); hemangiopericytoma (n = 1); ameloblastoma (n = 1), and osteosarcoma (n = 1).
  • Twenty-eight patients had a maxillectomy or other sinus surgeries, 10 had radiotherapy, and 14 had chemotherapy and radiotherapy before DCR.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Ethmoid Bone / surgery. Female. Humans. Male. Maxilla / surgery. Middle Aged. Paranasal Sinuses / surgery. Radiotherapy, Adjuvant. Recurrence. Retrospective Studies. Sphenoid Bone / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15565560.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Uchida D, Shirato H, Onimaru R, Endou H, Aoyama H, Tsuchiya K, Nishioka T, Homma A, Furuta Y, Fukuda S, Miyasaka K: Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery. Cancer J; 2005 Mar-Apr;11(2):152-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery.
  • PURPOSE: Ethmoidal malignant tumors, for which intensity-modulated radiotherapy is expected to improve outcome, consist of heterogeneous pathological types.
  • Reports about their outcome are influenced by the inclusion of favorable histology, such as adenocarcinoma and adenoid cystic carcinoma.
  • We investigated the long-term treatment outcome of squamous cell carcinoma and undifferentiated carcinoma of the ethmoid sinus.
  • Radiation dose varied from 50.4 Gy in 16 fractions (50.4 Gy/16 Fr) to 65 Gy in 26 fractions with or without stereotactic boost irradiation.
  • Eleven patients received chemotherapy consisting mainly of platinum-based compounds.
  • CONCLUSION: Ethmoid squamous cell carcinoma or undifferentiated carcinoma was diagnosed at advanced T stages and was treated with radiotherapy; these patients had a poorer outcome than patients with adenocarcinoma or adenoid cystic carcinoma.
  • Prospective trials using advanced technology should be carefully compared with historical controls because pathological types can considerably influence the treatment results.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Ethmoid Sinus / pathology. Paranasal Sinus Neoplasms / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15969991.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Ferguson MJ, Dewar JA: Locally recurrent adenoid cystic carcinoma of the left antrum: response to epirubicin, cisplatin and 5-fluorouracil. Clin Oncol (R Coll Radiol); 2001;13(3):236-7
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally recurrent adenoid cystic carcinoma of the left antrum: response to epirubicin, cisplatin and 5-fluorouracil.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Neoplasm Recurrence, Local / drug therapy. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Disease-Free Survival. Epirubicin / administration & dosage. Fluorouracil / administration & dosage. Humans. Magnetic Resonance Imaging. Male. Maxillary Sinus / pathology. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11527304.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement